Novavax's (NVAX) RSV vaccine is "under-appreciated," FBR says, adding that the company's pandemic vaccine program is "even less well appreciated."
The new note largely echoes similar research out last month, but analyst William Tanner's language regarding the company's pandemic program looks a bit more upbeat. "Investors should ignore the program no more," Tanner says, adding that "contrary to the belief that [recent AH7N9] data had already been released, they were, in fact, a new disclosure."
NVAX is rated Outperform.
Price target remains $11.